Jacob Thaysen
Jacob Thaysen's purchase track record
Jacob Thaysen has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/12/2025 | ILMN | $999K | +16.2% | +49.2% | +16.9% |
| 2/22/2024 | ILMN | $992K | -21.9% | -1.9% | +9.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Agilent to acquire Proscia for up to $270M. Agilent Technologies has agreed to acquire digital pathology specialist Proscia in a deal valued at up to $270 million. The move is designed to strengthen Agilent's position in AI-enabled diagnostics and scientific intelligence. Following the announcement, TD Cowen raised its price target for the stock to $196.
Transaction History
| ILMN | ▼ Sell | Tax Withholding | 1,303 | $383K | 10/5/2026 | View on chart |
| ILMN | ▲ Buy | Grant | 25,734 | $3.3M | 3/5/2026 | View on chart |
| ILMN | ▼ Sell | Tax Withholding | 6,544 | $762K | 2/15/2026 | View on chart |
| ILMN | ▲ Buy | Option Exercise | 13,264 | $0 | 2/12/2026 | View on chart |
| ILMN | ▼ Sell | Tax Withholding | 5,470 | $626K | 2/12/2026 | View on chart |
| ILMN | ▼ Sell | Tax Withholding | 1,301 | $131K | 10/5/2025 | View on chart |
| ILMN | ▲ Buy | Open Market | 4,946 | $399K | 5/13/2025 | View on chart |
| ILMN | ▲ Buy | Open Market | 804 | $66K | 5/13/2025 | View on chart |
| ILMN | ▲ Buy | Open Market | 100 | $8K | 5/13/2025 | View on chart |
| ILMN | ▲ Buy | Open Market | 1,400 | $114K | 5/12/2025 | View on chart |
| ILMN | ▲ Buy | Open Market | 1,200 | $96K | 5/12/2025 | View on chart |
| ILMN | ▲ Buy | Open Market | 200 | $17K | 5/12/2025 | View on chart |
| ILMN | ▲ Buy | Open Market | 3,700 | $299K | 5/12/2025 | View on chart |
| ILMN | ▲ Buy | Grant | 28,709 | $0 | 3/5/2025 | View on chart |
| ILMN | ▼ Sell | Tax Withholding | 2,064 | $209K | 2/15/2025 | View on chart |
| ILMN | ▼ Sell | Tax Withholding | 914 | $129K | 10/5/2024 | View on chart |
| ILMN | ▲ Buy | Grant | 22,276 | $0 | 3/5/2024 | View on chart |
| ILMN | ▲ Buy | Grant | 7,426 | $0 | 3/5/2024 | View on chart |
| ILMN | ▲ Buy | Open Market | 5,085 | $686K | 2/22/2024 | View on chart |
| ILMN | ▲ Buy | Open Market | 1,553 | $211K | 2/22/2024 | View on chart |
| ILMN | ▲ Buy | Open Market | 692 | $95K | 2/22/2024 | View on chart |
| ILMN | ▲ Buy | Grant | 7,531 | $0 | 10/5/2023 | View on chart |
| A | ▼ Sell | Open Market | 3,235 | $504K | 12/1/2022 | View on chart |
| A | ▼ Sell | Open Market | 9,700 | $1.5M | 11/30/2022 | View on chart |
| A | ▼ Sell | Tax Withholding | 1,418 | $207K | 11/18/2022 | View on chart |
| A | ▼ Sell | Tax Withholding | 537 | $78K | 11/17/2022 | View on chart |
| A | ▼ Sell | Tax Withholding | 403 | $59K | 11/16/2022 | View on chart |
| A | ▲ Buy | Grant | 4,287 | $634K | 11/15/2022 | View on chart |
| A | ▲ Buy | Grant | 26,029 | $3.9M | 11/15/2022 | View on chart |
| A | ▼ Sell | Tax Withholding | 12,438 | $1.8M | 11/15/2022 | View on chart |
| A | ▼ Sell | Tax Withholding | 1,091 | $162K | 11/11/2022 | View on chart |
| A | ▼ Sell | Open Market | 5,839 | $803K | 9/9/2022 | View on chart |
| A | ▼ Sell | Open Market | 5,879 | $749K | 6/2/2022 | View on chart |
| A | ▼ Sell | Tax Withholding | 183 | $22K | 5/13/2022 | View on chart |
| A | ▼ Sell | Tax Withholding | 1,418 | $233K | 11/19/2021 | View on chart |
| A | ▼ Sell | Tax Withholding | 536 | $87K | 11/17/2021 | View on chart |
| A | ▼ Sell | Tax Withholding | 14,579 | $2.4M | 11/16/2021 | View on chart |
| A | ▲ Buy | Grant | 26,460 | $4.3M | 11/16/2021 | View on chart |
| A | ▲ Buy | Grant | 3,248 | $524K | 11/16/2021 | View on chart |
| A | ▼ Sell | Tax Withholding | 839 | $135K | 11/12/2021 | View on chart |
| A | ▼ Sell | Tax Withholding | 1,091 | $176K | 11/12/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Illumina Launches BioInsight Platform Amid AI Drug Discovery Trends
Illumina introduced its BioInsight Platform, a new unified software environment designed to speed up genomic and multiomic research. This move aligns with broader industry trends, including the recent $150 million IPO of AI drug discovery firm Iambic. Analysts are currently evaluating whether the stock's current valuation reflects these strategic shifts in AI and diagnostics.
Illumina Launches BioInsight Platform Amid AI Drug Discovery Trends. Illumina introduced its BioInsight Platform, a new unified software environment designed to speed up genomic and multiomic research. This move aligns with broader industry trends, including the recent $150 million IPO of AI drug discovery firm Iambic. Analysts are currently evaluating whether the stock's current valuation reflects these strategic shifts in AI and diagnostics.